Among other topics, this program will address:
- Proxy access
- Shareholder proposal trends
- Say-on-pay and say-when-on-pay votes
- Voting policy changes from proxy advisory firms
- Board composition and trends
- Other trends in corporate governance
- SEC rulemaking update
Panelists
- Joshua Agen, Partner, Foley & Lardner LLP
- Curt Creely, Partner, Foley & Lardner LLP
- Richard Grubaugh, Senior Vice President, D.F. King & Co., Inc.
- Patrick McGurn, Special Counsel and Head of Strategic Research and Analysis, Institutional Shareholder Services
- John Wolfel, Partner, Foley & Lardner LLP
There is no cost to participate in this program, but pre-registration is required. To participate, please use the Register Today button above or below, or simply register here. Instructions for accessing the program will be sent in your confirmation email.
We look forward to having you join us. For more information, please visit Foley.com/NDI or contact Harrison Papadakis at hpapadakis@foley.com.
Josh Agen, Curt Creely, and John Wolfel are the Foley attorneys responsible for this program.
People
Related Insights
June 6, 2025
Energy Current
House Bill 3809 Adds Obligations to Battery Energy Storage Lessees in Texas
On May 29, 2025, House Bill No. 3809 was signed into law by Texas Governor Greg Abbott. Born out of a crop of bills regulating renewable…
June 23, 2025
Events
Third Annual Transaction Solutions Symposium
Foley & Lardner is sponsoring the Third Annual Transaction Solutions Symposium — a premier conference focused on de-risking strategies that enhance deal execution and business outcomes. Rishi Sodhi will be speaking as part of the Tax Liability Insurance: Current Trends, Controversies and Claims panel.
June 5, 2025
Health Care Law Today
GLP-1 Compounded Medications Targeted by Connecticut Attorney General
On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight loss clinics, med spas, medical practices and other businesses regarding allegedly or potentially unfair and deceptive conduct relating to compounded GLP-1 medications.